LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the publication of data from partner Sensory Cloud detailing the utility of FEND, a hypertonic calcium chloride salt solution with nasal mister, in the reduction of bioaerosol generation in the airways. Pulmatrix licensed the rights to the Company's NasoCalm proprietary formulations (PUR003 and PUR006) to Sensory Cloud, now integral to the product FEND, with Sensory Cloud to market and distribute FEND, and Pulmatrix to receive escalating royalties, upon commencement of sales.
The publication, titled "Nasal Calcium-Rich Salts for Cleaning Airborne Particles from the Airways of Essential Workers, Students and a Family in Quarantine" and published in the journal Molecular Frontiers, was co-authored by Dr. David Edwards of Harvard (founder of Sensory Cloud), Dr. Robert Langer of MIT, and colleagues. Key findings of the study include:
"We are pleased to announce the publication of data from our partners at Sensory Cloud which demonstrate the utility of FEND to reduce bioaerosol production across a diverse set of subjects," said Ted Raad, Chief Executive Officer of Pulmatrix. "FEND, originally developed as NasoCALM by Pulmatrix, was shown, in combination with Sensory Cloud's FEND Mister, to effectively reduce exhaled particles even in subjects who were Super Spreaders, as well as a COVID-19 patient with acutely increased bioaerosol production. Importantly, administration of FEND reduces even the smallest aerosol particles which are not blocked by current hygiene practices including mask wearing and social distancing. These data further increase our confidence that FEND may be an important new option to improve hygiene in the wake of the pandemic and we look forward to continued progress as Sensory Cloud advances its plans for commercial launch on a global scale."
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact, and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the impact of the novel coronavirus (COVID-19) on the Company's ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates, including the failure to maintain our collaboration with Cipla Technologies, LLC; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the SEC, including its annual report on Form 10-K filed with the Securities and Exchange Commission on March 26, 2020 as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Timothy McCarthy, CFA
SOURCE Pulmatrix, Inc.